VAM
CLDX icon

Visium Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Visium Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,160
Closed -$485K – 1160
2015
Q1 		$485K Buy
+1,160
New +$415K 0.01% 693

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Visium Asset Management's CLDX Position: Q2 2015 in Review

Visium Asset Management sold out of Celldex Therapeutics (CLDX) in Q2 2015, closing a stake of 1,160 shares — an estimated $485K sold.

Visium Asset Management first reported a position in CLDX in Q1 2015 and held it in 1 quarter. The position peaked at $485K in Q1 2015. 186 funds tracked by Wall St. Rank hold CLDX as of Q2 2015.

  • Visium Asset Management reported no remaining Celldex Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Visium Asset Management sold 1,160 Celldex Therapeutics shares in Q2 2015, an estimated $485K.
  • Visium Asset Management first reported a position in Celldex Therapeutics in Q1 2015 and held it in 1 quarter.
  • Visium Asset Management's Celldex Therapeutics position peaked at $485K in Q1 2015.
  • 186 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2015.

Based on Visium Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.